RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

Neuro,

Did I hear correctly that the AD trials were being "re-started?" Why "re-started?" I thought they were continuing, even as the FDA issues in ADHD were being addressed.

Also, did I hear correctly the cellular abnormalities showed up in the 7-day rat study, but not in the longer rat and monkey studies? Is this the reason that Stoll thinks that the histo procedure might be the cause of the cellular abnormalities. (He seemed to backtrack from that position by saying that the abnomalities still showed up, but not to the same extent, when a different histo procedure was used. These points were very unclear to me.)

Stoll semed to indicate that other company's studies could impact COR's Ampakine platform, but yet seemed assured that this was not a platform-wide problem. There seems to me to be a contradiction here. I don't see how Stoll can be so sure this is not a platform-related problem.

How important do you think it is to the FDA's decision-making bodies that the tox studies are clean, but COR can't identify the root cause of the histo problem?

The sense I got from Stoll on the CC is that he thought CX717 development in ADHD was really a thing of the past. What COR learned was important and there was some "proof of principle," but this molecule really had to give way to a more powerful molecule that could be delivered at lower dosages.


Bladerunner